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The primary was to determine if a pictorial medication calendar would improve patient 
adherence to supportive medication regimens for adult patients receiving chemotherapy 
treatment. The secondary objectives were to: a) assess if the pictorial medication calendar 
would improve concordance with prescribed supportive care medication regimens, b) 
assess patient satisfaction associated with using the calendar and c) determine whether 
this tool affects participants' quality of life. 
METHODS 
Prospective, open-label, RCT with participants randomly assigned 1:1 to receive either 
routine care or routine care plus the intervention. Adherence was measured using pill 
count and diary. Concordance was measured by assessment of symptoms of nausea and 
vomiting in relation to PRN antiemetic use. Medication use and self-efficacy was 
evaluated using the MUSE scale. Participant satisfaction was evaluated using surveys 
created by the research team. A correlation analysis was performed between pills 
dispensed and taken as per the different adherence tools and a line of best fit was plotted 
where possible. A mean score difference was performed for the MUSE Scale results from 
baseline to end of study. A regression analysis was performed to determine if the 
symptoms of nausea and vomiting could predict the number of PRN anti-emetics taken. 
Data on participant satisfaction was analyzed graphically.  
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RESULTS 
The correlation between scheduled pills dispensed and taken as per pill count was 
p<0.001, r=0.96.  The correlation between scheduled pills dispensed and taken as per the 
diary was p=0.015 and r=0.71. The correlation between the PRN number of pills taken as 
per the pill count and average symptoms recorded in the diary was r=0.65 and p=0.06. 
The correlation between the number of PRN pills taken as per the diary and the average 
symptom score was p=0.47, r= 0.28 and between the PRN pills taken as per the diary and 
the number as per the pill count was p=0.19 and r=0.49. For the regression analysis 
model that assesses whether symptoms can predict PRN medication use in the 
intervention arm, F (2,3)=7.24, r2=0.8284, adjusted r2=0.7141, p=0.035. Due to the low 
number of participant data in the control arm, a regression analysis was not possible. The 
line of best fit for the intervention arm was y=-0.09x+3.06, R² = 0.05 and for the control 
arm, y=1.11x+0.16, R² = 0.92. For the intervention arm, the mean of score difference for 
the MUSE scale was 0.7, std. dev. = 4.40. For the control group arm the mean of the 
score difference of the MUSE scale was 1.86, std. dev.= 4.99. The alternative hypothesis, 
Ha: diff>0, where Pr (T>t)= 0.67, t (15)=  -0.46 was chosen. Of the 17 participants for 
which results were available for the survey, 8 of the intervention group participants and 3 
of the control group participants completely disagreed that the medication regimen was 
complicated, 1 participant in the intervention group and 2 in the control group moderately 
disagreed, none of the participants neither agreed nor disagreed, 1 in the intervention arm 
and 2 in the control arm moderately agreed and no participants completely agreed.  
Participants that received the calendar found it useful for medication taking behaviours. 
Approximately 80% of participants either moderately or completely agreed that the diary 
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helped keep track of medications, with which medications to take, when to take them and 
how many times per day.   
DISCUSSION 
There appeared to be a correlation between scheduled pills taken as per the pill count and 
as per the diary, however the correlation was not statistically significant. Participants in 
both arms tended to take the majority of all prescribed medications according to both pill 
count and diary. There appeared to be a trend towards predictability of PRN anti-emetic 
use with increased symptoms, however this trend was only visible with pill count and not 
with the ORN anti-emetic pills taken as per diary recording. The MUSE scale results 
between the intervention and control arm did not appear to be significantly different. Of 
the intervention arm participants who answered the questions related to the calendar, the 
majority either moderately or completely agreed that it was a useful tool. Therefore, at 
this point it cannot be assumed that medication use and self-efficacy is improved with the 
use of the calendar. Participants in the control arm found the treatment regimen less 
complicated overall. The pictorial medication calendar tool may have played a factor in 
this response as those in the intervention arm would have not only been given routine 






Therefore, it appeared that the calendar was a useful tool, subjectively to participants 
involved in the study for ease of medication use. Furthermore, it also appears that 
participants who received the diary felt that their regimen was less complex. However, at 
this point it cannot be stated that the tool significantly affects adherence in a statistically 
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Adherence, for the purpose of this thesis is defined as the degree to which a 
patient’s medication behaviours correlate with the therapeutic recommendations agreed 
upon with their treating care provider, and is an essential component of drug therapy(Font 
et al., 2017).  
A Cochrane review focusing on interventions that affect “adherence”, quantify 
adherence as the number of doses taken of a prescribed agent divided by the number of 
doses prescribed (Haynes et al., 2005). A calculation of adherence, which will be used as 
a basis of hypothesis generation and for the purpose of calculating a numerical adherence 
for this document, can also be found in the figure below (Figure	1).  
FIGURE 1: CALCULATING SELF-REPORT ADHERENCE 
 
FIGURE	1	
Adherence has also had historical difference when gender was taken into 
consideration with one study indicating that women were less likely than men to be 
adherent to chronic medications prescribed (Manteuffel et al., 2014). Furthermore, 
another study that assessed factors which affect gender difference in medication 
adherence that focus on management of hypertension also re-asserts the fact that male 
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participants adherence more effectively than female participants do (Chen, Lee, Liang, & 
Liao, 2014). Therefore, it must be taken into deliberation that depending on the gender of 
a particular population, especially when a disease is predominate to one gender over 
another, such as breast cancer being more frequent in females and prostate cancer found 
solely in males, demographic factors must be noted.  
Although adherence in the traditional sense focuses on how well patients comply 
with a prescribed medication regimen, adherence also must take into consideration the 
symptoms that participants are experiencing on medications, tolerability of medications, 
pill burden and other external factors, such as cultural beliefs and socioeconomic factors.  
According to data from the World Health Organziation and a study by Brown & 
Bussell, adherence to long-term therapy for chronic illnesses in developed countries 
averages approximately 50% (Sabate, n.d.), (Brown & Bussell, 2011). In consequence, 
non-adherence may lead to reduced efficacy and increased healthcare costs.   
These approximate estimates are at times an over-estimation due to self-reporting 
of data. A review on medication adherence by Matsui in 2013 states that the more 
complex and convoluted a medication regimen is, the less likely that it will be followed 
(Matsui, 2013). The author also states that poor medication adherence is common and at 
times prevalent in multiple disease conditions where the lack of adherence can potentiate 
failure of therapeutic goals and lead to worsening illnesses (Matsui, 2013).  
There are a multitude of reasons why non-adherence occurs, which includes 
factors such as poor communication between the health care professional and the patient, 
a cognitive inability to understand instructions given, possible intentional non-adherence 
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(Morrow, Leirer, & Sheikh, 1988) and other sometimes, patient specific reasons. 
Therefore, tools, education and other modalities must be synergistically applied in order 
to improve patient adherence to medication regimens. 
Poor adherence to drug therapy can take multiple forms including, but not limited 
to not having prescriptions filled for a disease state, and not strictly following or 
discontinuing medication regimens without consultation with a health care professional 
(Matsui, 2013). Patient non-adherence can also be related to unpleasant side effects of the 
medication, lack of education on medication administration, or convoluted medication 
regimens (Claxton, Cramer, & Pierce, 2001; Kreps & Sparks, 2008; Shrank & Avorn, 
2007).  
Aside from adherence being due to changes in the use of a prescribed medication 
by a knowing participant, it may also be due to reduced health literacy. In the United 
States, approximately half of patients have poor health literacy (Shrank & Avorn, 2007), 
which can propagate confusion and an inability to adhere to medication regimens, even if 
the intent is to do so.  
A study by Kreps and Sparks has shown that patients with low health literacy 
often have difficulty comprehending medical instructions; amongst this group, pictorial 
aids have been found to be helpful (Kreps & Sparks, 2008). Although the majority of the 
literature focuses on visual aids being effective in the lower health literacy population, 
patients often use pictures and words in information monographs to guide their 




ADHERENCE IN THE ONCOLOGY POPULATION 
In recent years there has been significant progress in treatment of oncologic 
processes, which has been accompanied by increased regimen complexity. Patients must 
not only grasp the regimens and side effects associated with chemotherapy and 
indications of supportive care medications in the oncology setting but must also 
remember when certain medications are to be taken. Due to the increasing complexity 
and at times overwhelming nature of disease treatment, there is a significant focus on 
maintaining and improving quality of life of individuals living with cancer and their 
caregivers (Canadian Cancer Society’s Advisory Committee on Cancer Statistics., 2016). 
Adherence to oncologic regimens, as well as the supportive care regimens accompanying 
chemotherapeutic and biologic treatments, is an essential component of managing the 
oncologic process and ensuring that the quality of life of patients is as optimal as possible.   
A study by Font et al. notes that adherence to neo-adjuvant treatment utilizing 
capecitabine varied from 100% on clinical history, 83% on self-report and 67.9 % on pill 
count (Font et al., 2017). This data is cause for alarm as studies that exist in the literature 
to assess efficacy, disease free progression and cure rates generally require exceptional 
follow-up and adherence. Furthermore, the authors note that self-reported adherence has 
historically tended to over-estimate true adherence (Font et al., 2017). Therefore, when 
utilizing tools, such as diaries, which require a subjective recording of the participant’s 
medication use behaviour, the investigator must be aware that the values attained may 
over-estimate true use. 
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In another study that assessed medication adherence to oral cancer therapies, 
adherence ranged from 20 to 100% (Felton, van Londen, & Marcum, 2016), which is a 
wide and concerning range.  This wide range of adherence to oral cancer therapies creates 
a difficulty in deciding what is the goal, or expected adherence to these medications in 
the real world.  
In a report that compared non-adherence with adjuvant anastrozole therapy using 
three separate databases in the same population, estimates of non-adherence varied from 
32-50% (Patridge, AH, LaFountain, A, Mayer, E, Taylor, BS, Winer, E, Asnis-Alibozek, 
2008). Another study regarding adherence in tamoxifen users ranged from 41-88%, 
whereas adherence in aromatase inhibitor users ranged from 50-91% (Murphy, 
Bartholomew, Carpentier, Bluethmann, & Vernon, 2012). 
Outside of adherence to the chemotherapeutic agents, compliance with supportive 
medication use, such as agents used to manage nausea and vomiting area also important.  
CINV is a significant and distressing problem for patients receiving moderate or highly 
emetogenic chemotherapy (Gilmore et al., 2014). Multiple supportive care medications 
have been used to manage or prevent CINV (Gilmore et al., 2014), however, patients 
must be educated and sometimes reminded on the appropriate use of these supportive 
care medications due to the complexity of the regimens.  
Adherence to chronic medication use, such as tamoxifen regimens which persist 
for 5 years or more and that associated with short courses of anti-emetics used around 
neo-adjuvant or adjuvant chemotherapy, is quite different and may not be extrapolatable 
to short bursts of drug therapy. A patient receiving an anti-emetic regimen has to comply 
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to multiple and different pills taken per day for on a general basis 3 to 5 days, however a 
patient taking tamoxifen uses the same dose every day for many years. Whether 
adherence would be better in one group versus the other is not clear. 
FURTHER COMPLEXITIES OF ADHERENCE 
Aside from the complexity and side effects associated with oncological regimens, 
many cancers affect Canadians aged 50 years and older more than other age groups 
(Canadian Cancer Society’s Advisory Committee on Cancer Statistics., 2016). This 
population may be at higher risk of concomitant illnesses such as diabetes, hypertension 
(Yancik, R., 1997) as well as memory decline and, thus, require a multitude of other 
medications for the management of these chronic illnesses. The pill burden associated 
with chronic disease state management as well as supportive-care medication 
management for oncological regimens creates a more complex picture, which can 
increase non-adherence. Furthermore, confusion secondary to the disease states 
themselves, such as cognitive decline, sedation secondary to anticholinergic agents or 
other drug-induced adverse effects reduce the patient’s ability to comply with and 
remember medication instructions. 
Elderly patients may have difficulty reading and understanding drug labels such 
that only 40% of older patients in a particular study clearly understood how to properly 
take medications (Shrank & Avorn, 2007). It must be taken into consideration that the 
much older adult population would be more likely to suffer from visual and hearing 
impairment and have difficultly understanding instructions due to reasons other than poor 
compliance or medication taking behaviours.  
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A post-hoc analysis was performed by the Kripalani et al., which found that 
medication schedules led to significantly greater odds of adherence for those who had 
more than eight medications at baseline (OR=2.2; 95 % CI, 1.21 to 4.04) (Kripalani, 
Schmotzer, & Jacobson, 2012).  
A study by Ngoh L and Sheperd M., on the use of visual aids for communicating 
prescription drug instructions to non-literate patients found that culturally sensitive visual 
aids presented in a pictorial format significantly improved comprehension and 
compliance to the antibiotic agents prescribed (Ngoh & Shepherd, 1997). The authors 
stipulated from previous literature that there are key aspects, which make visual aids 
effective. The first is that the visual aid must get the participant’s attention and must be 
representative of the object it is to emulate (Ngoh & Shepherd, 1997). Secondly, visual 
representations must be culturally sensitive (Ngoh & Shepherd, 1997). Lastly, the 
clinician must take into consideration that the tool is generally developed by a 
professional and is often unable to capture the cultural references that must be applied to 
be understood (Ngoh & Shepherd, 1997). Therefore, multiple considerations must be 
noted when creating adherence based regimens and tools to improve medication taking 
behaviours of patients.  
Shrank et al. elude to the fact that information labels and inserts are generally 
significant sources of information for patients when determining the benefits and risk of 
adverse effects associated with medication administration, however the quality of this 
information often varies significantly (Shrank & Avorn, 2007). Therefore, 
standardization of education and information tools aimed at improving medication taking 
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behaviours and ensuring that tools take into consideration patient key beliefs and values 
would create more effective tools.  
ADHERENCE TOOLS IN THE LITERATURE 
Adherence is a multifactorial concept that depends on a chain of communication 
that encompasses many stakeholders from physician, to pharmacist, nursing staff and the 
patient (Morrow et al., 1988). The process of medication taking is not simple and has 
many areas where errors are possible. First, the physician must write a prescription for a 
medication, then the patient must take the prescription to be filled at a pharmacy (Morrow 
et al., 1988). The pharmacist must then dispense the correct medication and guide the 
patient on appropriate therapy, which often does not take into consideration the pill 
burden of multiple medications (Morrow et al., 1988). Even with modern day technology 
where prescriptions can be written on a computerized interface and sent to a pharmacy 
directly, the same process applies where a prescription must pass between prescriber, 
pharmacist and patient.  
The patient must then remember to take the correct dose at the right time and 
remember all drug and food interactions that were discussed with the prescriber and 
pharmacist (Morrow et al., 1988). All of these factors are often complicated without any 
external factors, however when cognitive impairment or another adherence impeding 
factor is brought into the equation, adherence becomes much more difficult. Therefore, 
tools to reduce the complexity of the regimen or to act as a reminder to patients are 
possible methods to improve adherence.  
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According to Kreps et al., health communication and education messages must be 
strategically designed to meet unique needs and communication orientations of target 
audiences (Kreps & Sparks, 2008). Messages should be designed to meet key beliefs, 
attitudes and values of the target population and ensure that messages, language, and 
illustrations are appropriate (Kreps & Sparks, 2008). Adherence interventions, including 
educational material and programs as well as written instructions and calendars are 
helpful but often-labor intensive and not feasible in a clinical setting (Morrow et al., 
1988). However, if an intervention can be simplified in order to reduce clinician 
workload, the intervention may be not only effective, but also feasible.  
There are multiple medication adherence strategies that exist in the literature, 
including medication vial caps that remind patients to take medications and phone 
application reminders (Felton et al., 2016). However, according to a review of the 
literature on the use of pictorial aids in medication instructions, humans tend to have a 
cognitive preference for pictures (Katz MG, 2006). Also, a combination of text and 
pictorial instruction appears to be more effective than either format alone to improve 
adherence to medications (Katz MG, 2006). Katz, the author of a review article on visual 
aids and medication adherence alludes to the need for pictorial depictions to be realistic, 
simple and have a clear singular meaning in order to be effective (Katz MG, 2006).  
Scientifically, there appears to be evidence suugesting that pictures aid in the 
development of a cognitive model that improves problem solving (Katz MG, 2006). 
Katz conducted a MEDLINE search of app data published between 1966 to 2005 
using terminologies such as “illustration, picture, pictograph, graphics, chart, image, 
photo, cartoon and drawings”(Katz MG, 2006). The authors also assessed search terms 
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which included “pill, medicine, pharmacy, prescription, etc.” (Katz MG, 2006). The 
following were key messages present in this review regarding increasing effectiveness of 
health communication that were focused upon when gathering information for the 
purpose of this thesis and was considered during the formulation of the research question 
for this RCT (Kreps & Sparks, 2008). First, individuals from the population of interest 
should be involved and empowered when creating a health communication method 
(Kreps & Sparks, 2008). Secondly, culturally appropriate messages and materials should 
be created (Kreps & Sparks, 2008). Thirdly, a focus should be placed on care providers 
and community members to deliver and reinforce messages (Kreps & Sparks, 2008).  
ADHERENCE METHODOLOGY IN THE LITERATURE 
A study by Dowse and Ehlers was conducted in 87 participants who attended an 
outpatient clinic and were prescribed a short course antibiotic (Dowse & Ehlers, 2005). 
The authors utilized previously developed and tested pictograms that were culturally 
sensitive and were printed on the reverse side of a re-sealable plastic packet routinely 
used in the region (Dowse & Ehlers, 2005). Participants received followed up 3 to 5 days 
after antibiotic initiation to test recall and understanding of the medication instructions  
(Dowse & Ehlers, 2005). Adherence was determined using self-reporting and pill or 
medication count (Dowse & Ehlers, 2005). The statistical analysis performed by study 
authors was a chi-squared test to assess for significant differences in demographic 
characteristics between the control and intervention group and to test for differences in 
understanding of medication instructions and adherence (Dowse & Ehlers, 2005). The 
influence of literacy on both understanding and adherence was investigated using a 
	 11	
correlation analysis and the level of significance was set at 1% (Dowse & Ehlers, 2005). 
According to the authors, the use of a pictogram enhanced patient comprehension (Dowse 
& Ehlers, 2005). 
Another study focused on simulated labels and compared the design of the labels 
to determine if text only, pictures only or text and words would affect patient 
understanding of medication instructions (Sansgiry, Cady, & Adamcik, 1997). The 
authors found that the method of label design significantly affected participant 
understanding of the medication instructions. The authors did not, however, find a 
significant difference between individuals that received text and picture versus text alone 
(Sansgiry et al., 1997).  
Another study was performed with low health literacy participants with difficulty 
understanding medication instructions at baseline (Kripalani et al., 2007). Participants in 
the intervention group received a card with medication name, indication and time of 
administration (Kripalani et al., 2007). The pill card was reported frequently use by the 
intervention group initially, however its use declined approximately 3 months later 
(Kripalani et al., 2007). Participants with lower health literacy utilized the pill cards 
regularly and found it helpful for remembering important medication information 
(Kripalani et al., 2007). Therefore, this tool was helpful for participants with lower health 
literacy according to the study results. 
Our hypothesized definition of adherence revolved around adherence to the 
prescribed supportive care regimen for nausea and vomiting 80% of the time for 
scheduled medications. The selection of 80% adherence rate is relatively arbitrary as the 
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actual adherence in the literature varied significantly. The assumed average adherence 
rate for the general oncology population that entered the study for treatment of adjuvant 
and neoadjuvant malignancies without the use of an adherence calendar was assumed to 
be an average of 60% according to the above-mentioned statistics (Sample	Size).  
PHARMACIST’S ROLE IN PATIENT’S MEDICATION TAKING 
BEHAVIOURS 
A study on the role of the pharmacist in medication adherence in the oncology 
setting supports the pharmacist’s role is multifactorial team environments, in that the 
pharmacist includes written and oral communication to the patient, counselling and 
follow-up over time as appropriate (Felton et al., 2016).  
A recent randomized controlled study conducted by the Ontario Pharmacists 
Association and Green Shield of Canada addressed the impact of pharmacist 
interventions in hypertension management on patient outcomes and discussed a few key 
strategies used to improve adherence ((OPA) & (GSC), 2014). The strategies involved a 
multi-modal approach that included: simplifying regimen characteristics, ensuring that 
patients understood the purpose of the medication, addressing the risks of non-adherence 
and benefits of treatment, communicating in a manner that is understandable to the 
patient and evaluating adherence ((OPA) & (GSC), 2014). This pharmacy led approach 
allowed for a quadrupling in the number of patients whose blood pressure was controlled 
and increased medication adherence by 15% ((OPA) & (GSC), 2014). 
Furthermore, according to multiple surveys summarized by Felton et al., patients 
in an ambulatory outpatient oncology clinic indicated that it was “absolutely necessary” 
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to discuss initial treatment with a pharmacist 86% of the time (Felton et al., 2016). Also 
in the same commentary article, 76% of participants requested that discussion with a 
pharmacist occur at follow-up visits (Felton et al., 2016).  Therefore, it is clear that the 
involvement of a pharmacist is invaluable to patients and the inclusion of a pictorial 
medication calendar to help guide discussion may result in better medication taking 
behaviour and understanding by the patient.  
Therefore, the above-mentioned examples allude to the necessity of a 
multidisciplinary and multi-modal strategy to improve adherence. This information is not 
specific to either hypertension or oncology and can be applicable to all adherence 
strategies. A major role of the pharmacist is to allow for patients to understand more 
thoroughly the purpose of the medications, how to use them and expected adverse effects 
associated with chemotherapeutic and supportive care medications prescribed.   
PURPOSE OF STUDY 
Secondary to the complexity of oncologic supportive care regimens, particularly 
in moderately or highly ematogenic and myelosuppressive chemotherapies, the author 
wished to examine if the use of a visual aid would improve patient adherence. A 
preliminary qualitative survey conducted by nursing staff and pharmacists in 2010-2011 
at the London Regional Cancer Program at London Health Sciences centre in London, 
Ontario using the pictorial medication calendar tool proposed in this study, generated 
very positive results regarding participant satisfaction with the pictorial medication 
calendar (Smith, 2012). The survey found over 80% of 38 patients moderately or 
completely agreed that the calendar helped them to better understand medications (Smith, 
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2012). Similar results were obtained from the healthcare staff, which saw this tool as a 
tremendous aid to patients (Smith, 2012). Over 95% of 29 staff agreed that the calendar 
helped their patients better understand what medications they needed to take and when to 
take them (Smith, 2012). The survey was intended to assess the usefulness of the tool 
from a health care provider and patient point of view and not to determine if the tool was 
effective in improving adherence or medication taking behaviours objectively.  
Therefore, an RCT was created to determine if this particular visual aid, a 
pictorial medication calendar created by an oncology pharmacist at the LRCP would 
improve adherence to supportive care medications and affect other medication taking 
behaviours of patients.  
The pictorial medication calendar is an amalgamation of pictures of the respective 
medications and instructions on how to take the medications (Figure	2). A figure in the 
supplemental literature of this thesis provides an example of these pictorial medication 
calendars ((Figure	2). The calendars are created by LRCP pharmacists and can be saved 
and modified by the pharmacy team. The calendars are then printed in colour to allow for 
patients to have not only instructions on the vials to guide their medication taking 
behaviours but also another learning tool, which activates different parts of the brain to 
ensure learning and understanding are multifactorial (Katz MG, 2006).  
We proposed that use of this pictorial medication calendar tool would improve 
patient adherence and understanding of how to take medications through simplification of 
presentation and the addition of pictographic information. This tool allows the patient to 
see the medication regimen in a visual format.  The calendar can also be divided into the 
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various times of day that medications should be taken, followed by the corresponding 
symbols for each medication on the calendar, which allows patients to know which pill to 
take and when. This tool also has the potential to add in messages and comments about 
the medication at the bottom of the calendar (Figure	2). 
 
 








Our primary objective is to examine if this visual aid, the oncology pictorial 
medication calendar, improves patient adherence to oncology supportive care medication 
regimens for adult patients receiving treatment for adjuvant or neoadjuvant solid organ 
cancers using an open-label, randomized controlled study.  
Our secondary objectives are to assess whether the use of this medication calendar 
will improve concordance with prescribed PRN supportive care medication regimens, 
medication use and self efficacy with a focus on nausea and vomiting management, and 
patient satisfaction, and whether this tool helps to alleviate workload hours for pharmacy 





The null hypothesis would argue that the use of a pictorial medication calendar 
does not affect adherence to scheduled anti-emetic regimens used alongside 
chemotherapy in the neo-adjuvant or adjuvant oncology population receiving treatment 
for a non-hematologic malignancy. The alternate hypothesis would argue that the use of a 
pictorial medication calendar does affect adherence, with those in the intervention group 
being able to take scheduled medications more effectively than those in the control group.  
MEDICATION USE AND SELF-EFFICACY (MUSE) 
The null hypothesis for MUSE scale results would state there would not be a 
statistically significant difference between the participant scores at baseline to end of 
study. The alternative hypothesis for the MUSE scale results would state that there is a 
statistically significant difference between the participant scores at baseline to end of 
study.  
SYMPTOM MANAGEMENT 
The null hypothesis is that the use of the pictorial medication calendar would not 
improve concordance between, PRN antiemetic use and symptom management of nausea 
and/or vomiting.  The alternative hypothesis would be that the use of the pictorial 




 The null hypothesis would state that participant satisfaction with the complexity 
of the anti-emetic regimen would not be affected by the use of pictorial medication 
calendar. Furthermore, the null hypothesis would also argue that participants receiving 
the intervention would not be more satisfied than the neutral response with medication 
use behaviour outcomes. The alternative hypothesis would argue that the use of the 
pictorial medication calendar is associated with higher satisfaction in the intervention 
population with the anti-emetic regimen’s complexity. Also, those who receive the 
intervention would completely agree with the usefulness of the tool for medication taking 





EXPERIMENTAL DESIGN  
A prospective, open-label, randomized controlled study was conducted in the 
outpatient oncology setting. Participants were randomly assigned in a 1:1 manner to 
receive routine care versus routine care plus the medication calendar. Routine care 
consisted of an oncology pharmacist counselling the patient prior to the patient receiving 
their medications. The intervention group involved the oncology pharmacist using the 
computer system to print a medication calendar for the patient and explaining the 
calendar, in addition to routine care.  
Pharmacists were trained and provided a script to ensure that similar teaching was 
given to each participant is used in the two groups to reduce the risk of bias. Wording of 
the scripts for pharmacist counselling was as follows: 
For scheduled anti-emetics: 
This medication is used to help control your symptoms of nausea and/or vomiting. This 
medication is to be taken ___________ (regimen).  
For PRN anti-emetics: 
This medication is used when needed to control symptoms of nausea and/or vomiting. 
This medication is to be taken ___________ (regimen).  
A pharmacy procedure sheet and process flow diagram was made available to all 
LRCP pharmacy staff members to ensure a systematic process was followed (Figure	3). 
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FIGURE 3:  STUDY PROCESS 
Poster reviewed by Circle of Care for participant eligibility 
(All Team Members)
Participant meets eligibility 
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Notify CRU Personnel to ensure 
patient is not contacted again.
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Contact CRU Personnel as per poster 
for consenting and randomization.
CRU reviews Consent 
Information/Form         
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Satisfaction Survey
CRU to provide Feedback 
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Pharmacy staff member to perform pill count by visual check 




CRU to provide participant 
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"A Picture is Worth a Thousand Words" Project Process
Last Updated: June 11, 2016
FIGURE	3 
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Patients were included in the study only for the first two cycles of chemotherapy 
treatment to reduce heterogeneity since patients may receive a different total number of 
cycles.  
LOGISTICS 
The study was conducted at the LRCP for the duration of 9 months and it is 
intended that a further extension will be requested to ensure that 174 participants are 
recruited if possible (see statistics component under the heading (Sample	Size). LRCP has 
an annual patient flow of more than one million visits. As a part of LHSC, it is a well-
established teaching, research and health-care facility. LRCP also has a team of oncology 
pharmacists and a clinical research unit. This pictorial medication adherence calendar 
was first developed and pilot tested at the LRCP. Preliminary studies conducted in 2011 
at the LRCP included patients, nursing and pharmacy staff. Participants completed a 
survey to evaluate the pictorial medication calendar tool. The response rate for the 
patients was 75% (Smith, 2012). The results were very positive with over 80% of patients 
moderately or completely agreeing that the calendar helped them to better understand 
their medications and when to take them (Smith, 2012).  
INCLUSION CRITERIA 
Participants included adult male or female outpatients 18 years or older receiving 
chemotherapy treatment for neoadjuvant as well as adjuvant solid organ cancers. The 
primary populations enrolled included breast, colorectal and head & neck cancer. 
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Participants were on at least one scheduled antiemetic for management of chemotherapy-
associated nausea and vomiting and were also given one PRN antiemetic.  
Only participants able to provide consent for themselves were considered as this 
study assessed adherence of the individual patient to the medication regimen. In order to 
be able to provide consent, study participants must have been able to understand the 
instructions explained by the pharmacist for the adherence calendar and must have 
understood instructions provided by the Clinical Research Unit (CRU) consenting staff. 
Participants with speech or hearing impairment were given the opportunity to 
communicate in writing with the investigators. 
EXCLUSION CRITERIA  
Participants who had not attained a minimum of a grade 8 education as well as 
non-English speaking individuals were excluded since fluency with the English language 
was necessary to interpret the medication calendar. Currently the calendar is only 
available in the English Language.  
If the participant was unable to repeat the instructions back to research personnel 
at baseline, or becomes increasingly confused as time progressed, or a care provider had 
to speak on the participant's behalf, the participant was withdrawn from the study. 
Participants were also withdrawn from the study if follow-up became difficult because 
participants were frequently rescheduled or missed.  
Participants with difficulty swallowing and who required liquid formulations of 
medications were excluded from the study as the supportive care medication pictures 
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used for the calendars are created to take into consideration the pill format of 
medications.  Participants who might eventually require liquid formulations of anti-
emetics secondary to an oropharyngeal cancer or radiation therapy to the head or neck 
were included and re-assessed as required if swallowing difficulty developed.  
Participants planning to receive multiple cycles of chemotherapy at baseline at 
sites other than the LRCP were generally excluded from the study if the plan was clear 
from the outset of chemotherapy treatment due to lack of ability to follow-up with pill 
counts and adherence diaries for these individuals.  
Participants with a significant visual impairment that precluded the ability to read 
the pictorial medication calendar were excluded from the study. 
ETHICS BOARD APPROVAL 
The study personnel sought prior Research Ethics Board (REB) approval at 
Lawson Research Institute in London, Ontario and the University of Waterloo Ethics 
Board for the full study.  
Supporting documentation that were submitted and approved by the Ethics Boards, 
included: 
• Consent Form and Information (Appendix	A:	Information	and	Consent	Form), 
• Feedback Letter  (Appendix	B:	Feedback	Letter),  
• Study Poster (Appendix	C:	Study	Poster),  
• Accountability Log (Appendix	D:	Accountability	Log),  
• Adherence Diary (Appendix	E:	Adherence	Diary), 
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• Study Survey (Appendix	F:	Study	Survey) 
• Randomization and Enrollment Form (Appendix	G:	 Randomization	 and	 Enrollment	
Form), 
• Protocol Deviation Form (Appendix	H:	Protocol	Deviation	Form), 
• Visit Checklist (Appendix	K:	Unanticipated	Problems	Form),  
• Study Completion Form (Appendix	J:	Study	Completion	Form) 
• Unanticipated Problems Form (Appendix	K:	Unanticipated	Problems	Form) 
The study personnel intend on registering the study with clinicaltrials.gov.  
STUDY PROCEDURE 
The study investigators obtained consent from all attending physicians to 
approach patients for the study prior to enrollement of participants from each disease site. 
Physicians and CRU staff received a notification of an eligible participant. CRU 
personnel verified that the LRCP patient screened by a health care provider met the 
inclusion and exclusion criteria. CRU personnel discussed the study with the eligible 
patient and provided the patient with an informed consent form, if not already provided 
by the circle of care team member, to be completed up until the first day of the first cycle 
of chemotherapy. The study procedure flow diagram provides further information 
regarding the process of approaching eligible participants (Figure	3). 
If consent was obtained, the CRU then randomized the participant according to 
the randomization algorithm provided by the research personnel and notified the 
pharmacy team of the patient’s randomization status (Figure	 3). The pharmacist then 
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provided routine care, consisting of counselling the patient prior to the patient getting his 
or her prescription dispensed if randomized to the routine care arm. The pharmacist 
provided routine care and explained the medication calendar for the patient randomized 
to the intervention arm. Pharmacists were given a script that indicated general wording to 
be used when counselling participants in both the control and intervention groups. 
Pharmacy staff ensured that the accountability log (Appendix	D:	Accountability	 Log) was 
filled out for pill counts, counselling and notes where applicable.  
Before the patient left the LRCP on the first day of the first cycle of chemotherapy, 
CRU personnel provided the patient with a diary (Appendix	 E:	 Adherence	 Diary) to log 
information on the supportive care medication taken for nausea and vomiting, date, time, 
number of pills, and subjective assessment on a scale of 1 to 10 of the symptoms felt that 
day. Instructions for completion of the diary were on the first page. At the end of the first 
2 cycles of chemotherapy, the CRU provided a survey to all study patients (Appendix	F:	
Study	 Survey), which asked questions regarding satisfaction with their regimen’s 
complexity, satisfaction with the calendar for the intervention arm and demographic 
information.  
DATA RETENTION 
A Master Log was maintained in a locked filing cabinet at the study centre. Data 
was de-identified by ensuring each participant receives an alphanumeric code. A de-
identified data collection log was retained for study analysis purposes at the study centre.  
The hardcopy master list and consenting information sheets will be erased or 
placed in the confidential shredding bins 1 year from the date of completion of data 
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collection for this project as per Ethics Boards guidelines. Primary data documents (such 
as the diary, surveys and questionnaires) that were de-identified are stored at the study 
site for 5 years and will then be placed in the confidential shredding bins.  
Data that was de-identified and transferred to an electronic format via REDCap 
for analysis will be retained for 5 years and then erased. De-identified data that is shared 
between sites for analysis will be stored on an encrypted USB stick. 
RANDOMIZATION PROCESS 
A random sequence generated from “Random.org” was used to place participants 
in the intervention versus control arm (Dr. Haahr & Dr Haahr, 2017). The randomized 
sequence was used to create randomized manila envelopes numbered from 1 to 174 in 
sequence. A single co-investigator retained randomization sequence to ensure 
maintenance of study integrity only.  
ANONYMITY  
 Collected information that was not in print format and at the study site was stored 
on the study site’s private network on an encrypted server. Hardcopy data was de-
identified at initiation and entered into an electronic database, REDCap (Harris et al., 
2009). The hardcopy sheets that contained patient information with identifiers were 
stored only at the study site in a locked cabinet with study staff.  
A site computer was always used when entering and storing data that had 
identifiable variables.  If data sharing was required (e.g., when analyzing data), only de-
	 27	
identified data was shared using an encrypted memory stick or a secure e-mail transfer. 
Access to the patient records and location of information storage was limited to 
authorized personnel on the research team. REDCap (Harris et al., 2009), a secure web 
application for managing and storing the online surveys and databases was accessible to 
study personnel only.  
SAMPLE SIZE 
Based on previous research, (Patridge, AH, LaFountain, A, Mayer, E, Taylor, BS, 
Winer, E, Asnis-Alibozek, 2008),(Murphy, Bartholomew, Carpentier, Bluethman, & 
Vernon, 2012), (Katz MG, 2006) we estimated a 20-30% difference in adherence to 
medication between groups. Sample size was calculated to determine the range of 
patients required to compare two independent proportions with 80% power, a 5% 
significance level (2-sided), and a 10% attrition rate (Rosner, 2011): 
20% difference in proportion requires 87 patients per group 
30% difference in proportion requires 40 patients per group 
Thus, we estimated that data would be needed from between 40-87 patients in 
both groups to find a significant effect of adherence to medication. This results in a total 
estimated sample size of between 80-174 patients (Rosner, 2011); therefore, the upper 
bound of this interval was selected as the sample size. 
To correlate the sample sizes utilized for similar primary outcomes in the 
literature, previous studies were also assessed with similar study methodology. A study 
by Dowse and Ehlers assessing adherence using either text-only or text plus pictogram 
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required n=87 ((Dowse & Ehlers, 2005). Another study by Mansoor and Dowse designed 
to evaluate understandability of labels and patient information sheets with or without 
incorporation of a pictogram had a sample size of n=60 (Mansoor & Dowse, 2003). 
Although methodology was similar, statistical significance of difference in adherence 
related to pill count was not the primary outcome of either study.  
STATISTICAL ANALYSES AND DATABASES 
Microsoft Excel and STATA (StataCorp., 2015) were used to interpret the data 
that was attained from input into the REDCap database (Harris et al., 2009). Study data 
were collected and managed using REDCap electronic data capture tools hosted at the 
Lawson Research Institute (Harris et al., 2009).  
“REDCap (Research Electronic Data Capture) is a secure, web-based application 
designed to support data capture for research studies, providing 1) an intuitive interface 
for validated data entry; 2) audit trails for tracking data manipulation and export 
procedures; 3) automated export procedures for seamless data downloads to common 
statistical packages; and 4) procedures for importing data from external sources” (Harris 
et al., 2009). 
MEASURES OF ADHERENCE 
Adherence was defined as how well one takes a medication in relation to its 
prescribed dosing regimen (dose, interval and duration) (Zedler, Kakad, Colilla, Murrelle, 
& Shah, 11AD).  
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Adherence was measured in two distinct ways; using pill counts (Figure	 1, 
Appendix	D:	Accountability	Log) and a diary for patient self-tracking (Appendix	E:	Adherence	
Diary).  
The pill counts were utilized to calculate the number of missed doses or pills 
taken as percentage of the total number prescribed and dispensed (Zedler et al., 11AD). 
Pill count took place during follow-up visits with the pharmacy team at the study site. 
Patients were asked at study initiation to bring their anti-emetics in for a pill count and all 
unused medications were returned to the patient.  
A medication adherence diary (Appendix	 E:	 Adherence	 Diary) was also used to 
determine adherence from a patient’s point of view and to assess symptom management 
for the nausea and vomiting. The adherence diary asked participants to keep track of the 
anti-emetic medications taken every day for the first two chemotherapy cycles.  
The adherence rate between the pill count and diary entries was compared to 
determine inter-rater reliability (r). This was done to determine if the diary could be used 
as an independent and reliable tool for assessing adherence as the pill count was intended 
as a checking mechanism of adherence only rather than a measure in itself.  
Adherence and concordance information were compared, where possible, between 
the control and intervention arms to determine if any of these parameters were affected 
by the introduction of a medication adherence calendar.  
Adherence is a self-reported statistic and therefore pill count was compared to 
data reported in the diaries to determine agreement. A regression analysis was performed 
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on adherence data that was available from diaries to determine if there was a statistically 
significant difference in rates of adherence using pill count or in self-reported adherence.  
CONCORDANCE 
For medications to be taken PRN for nausea and vomiting symptoms, 
concordance was measured. Medications that are given on a flexible schedule, such as 
prochlorperazine 10mg every 4-6 hours PRN for nausea and vomiting, were measured in 
relation to the symptom being controlled.  
A self-assessment of adherence was created that presumed a gradient of how 
many pills a patient would take based on their symptoms of nausea and vomiting since a 
validated algorithm was not available in the literature (Table 1).  
TABLE 1: DETERMINING CONCORDANCE PERCENTAGES WITH PRN 
MEDICATIONS 
Score of Nausea or 
Vomiting 
Expected Percentage of Total 
Daily Doses Needed of PRN 
Medication 
Percentage Expected to be Correlated 
with Number of Pills Taken* 
(i.e.. prochlorperazine 10mg take one 
tablet every 4-6 hours PRN for nausea 
and vomiting) 
0 0 0 
1-2 20% 1 tablet 
3-5 40% 2 tablets 
6-8 60% 4 tablets 
9-10 80% 5 tablets 
* Rounding rules will be used to the nearest whole number 
TABLE 1 
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The proposed ratios in (Table 1) were an assumption and may not reflect the true 
pattern with which participants use the PRN nausea and vomiting supportive care 
medications.  
Concordance of the average nausea and vomiting symptoms over the two cycles 
with, PRN antiemetic use was calculated using a correlation and regression analysis.  
MEDICATION USE AND SELF EFFICACY 
  Patient understanding was evaluated using the Medication Use and Self Efficacy 
(MUSE) (Cameron KA, Ross EL, Clayman ML, Bergeron AR, Federman AD, Bailey SC, 
Davis TC, 2010) scale. The MUSE scale is a self assessment tool that was modified and 
validated from an existing scale (Communication and Attitudinal Self-Efficacy Scale) 
(Cameron et al., 2010). The MUSE scale is a valid and reliable tool that is intended to 
measure self-efficacy and understanding of the use of prescribed medications (Cameron 
et al., 2010).  
Participants were asked to complete the MUSE at the beginning and end of the 
study to determine if there was a change in the medication use and self-efficacy rating of 
participants between the beginning and end of their time n the study and also to determine 
if this was different between the two study arms. Correlation between scores was 






Participant satisfaction was evaluated using the investigator created surveys 
(Appendix	 F:	 Study	 Survey). These surveys asked questions regarding complexity of the 
chemotherapeutic regimens, satisfaction with the pictorial medication calendar for the 
intervention arm as well as demographic information.  Patient satisfaction surveys were 
completed at the end of the study. Patient satisfaction totals were tabulated for each 
question asked to determine overall subjective participant satisfaction with the pictorial 
medication calendar. Where applicable, a comparison between results in the intervention 
arm and control arm was planned.  
OTHER DATA COLLECTED 
Demographic information including gender, age and highest level of education 
attained were asked of participants in the study survey (Appendix	F:	Study	Survey). This 
information was tabulated and presented in chart format by intervention group.  
Information that may affect adherence related to supportive care regimen such as 
cycle length, number of times per day the that the participant takes non-oncologic 
medications and number of pills taken each time were collected to determine if the 






 33 participants have been enrolled thus far in the study; of those enrolled, 18 
participants have completed the study. Of the participants who have completed the study 
to date, 1 did not complete the forms for end of study, including MUSE scale, satisfaction 
survey and return of diary. Of the 17 participants who have finished the study to date, 7 
were randomized to the control arm and 10 were randomized to the intervention arm.  
Of the 17 participants who completed the study, 35.29% (6 participants) were 
male and 64.71% (11 participants) were female (Table 2). 30% of the intervention group 
participants and 43% of control group participants were male (Table 2). 
The average age in years of all participants was 59.17 with a SD of 2.91, with an 
age range of 37 to 78 years. The average age of participants in the intervention arm was 
57 years and in the control arm the average age was 63 years (Table 2). 
Of the 17 participants who completed the satisfaction survey, 2 participants 
attained a high school education, 6 participants attained a college education, 7 attained a 
university degree and 2 attained a post-graduate degree. The table found below provides a 
breakdown of education level by intervention arm (Table 2). 
On average, participants in the intervention arm took 3.3 medications that are 
unrelated to their oncology regimen on a daily basis, including prescribed and non-
prescribed medications and those in the control arm took 5.14 medications that are non-
related to their oncology regimen (Table 2). The average number of times per day that 
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non-oncologic medications were taken equated to 1.5 versus 1.71 in the intervention 
versus control arm, respectively (Table 2). 
TABLE 2: BASELINE DEMOGRAPHICS 




Average Age 62.71 56.70 
Male Participant  3 3 
Female Participant 4 7 
Grade School Education 0 0 
High School Education 1 1 
College 2 4 
University 3 4 
Post Graduate 1 1 
Average Number of Medications Unrelated to 
Oncology Regimen Taken per Day 
5.14 3.3 
Average Number of Times Per Day that Medication 





CALCULATIONS OF ADHERENCE 
Adherence was calculated using 2 different methods, pill count recorded in the 
accountability log (Appendix	D:	Accountability	Log) and a subjective daily diary (Appendix	
G:	 Randomization	 and	 Enrollment	 Form) recording that was done daily. The number of 
prescribed scheduled medications was totaled for each cycle for both the data attained 
from the pill count and the diaries.  
A correlation analysis was performed to determine the relationship between 
scheduled pills taken as per pill count performed by pharmacy and scheduled pills taken 
as per the adherence diary. The number of participants for which there was complete data 
for the diary was 11 out of 17, r=0.60 and p=0.05 (Table 3).  
A correlation was also performed to determine how strongly associated the 
number of dispensed pills were to the number of pills taken as per the pill count and as 
per the diary. The expected correlation would be 1, assuming that participants took all 
scheduled anti-emetics prescribed to them. The correlation between scheduled pills 
dispensed and scheduled pills taken as per pill count was r=0.96 and p<0.001. The 
correlation between scheduled pills dispensed and scheduled pills taken as per the 






TABLE 3: CORRELATION BETWEEN SCHEDULED MEDICATIONS 

















































A plot of the number of scheduled medications dispensed over the two cycles and 
the number of pills recorded in the patient’s diary that were taken is provided in a 
scatterplot (Figure	4). Of the 10 participants in the intervention, 2 participants had a pill 
count performed at baseline by a pharmacy staff member, but did not bring the anti-
emetic medications in for a pill count with each cycle (Figure	4). Of the 7 participants in 
the control arm, 4 participants were dispensed antiemetic medications for which the study 
personnel documented a pill count, however anti-emetic medications were not returned to 
pharmacy for a pill count (Figure	4). 
 
	 37	
FIGURE 4: PLOT OF NUMBER OF SCHEDULED PILLS DISPENSED 
AGAINST NUMBER OF PILLS TAKEN BY INTERVENTION ARM ON 
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PRN ANTI-EMETIC USE AND CORRELATION WITH SYMPTOMS OF NAUSEA 
VOMITING SCORE AVERAGED OVER 2 CYCLES 
A Spearman’s correlation analysis was performed due to the non-normalized 
distribution of the data on the number of PRN pills taken and the average symptoms of 
CINV over the first two cycles and also to correlate the pill count and entries recorded in 
the diary for PRN medication use. 7 of the 17 participants did not return their diaries and 
therefore average symptom score of nausea and vomiting could not be calculated for 
those participants, the spearman’s correlation was conducted by STATA on 9 study 
participants.   
The Spearman’s correlation coefficient between the number of PRN pills taken as 
per the pill count and average symptoms recorded in the diary was r=0.65 and 
p=0.06(Table 4). The Spearman’s correlation coefficient between the number of PRN 
pills taken as per the diary and the average symptom score was r= 0.28 and p=0.47 (Table 
4). The spearman’s correlation coefficient between the PRN number of PRN pills taken 





TABLE 4: SPEARMAN’S CORRELATION BETWEEN AS NEEDED 















































A regression analysis was performed to determine if the symptoms of nausea and 
vomiting could predict PRN medication use  (Table 5). There were 6 entries computable in 
the intervention arm and 3 in the control arm (Table 5).  For the regression analysis model 
that assesses whether symptoms can predict PRN medication use in the intervention arm, 
F (2,3)=7.24, r2=0.83, adjusted r2=0.71, p=0.04, 95% CI[0.028, 0.41], line of best fit from 
the regression analysis would be y= 0.22 (pill count) - 0.01 (diary) + 0.61 (Table 5). Due 




TABLE 5: REGRESSION ANALYSIS OF PRN PILL COUNT AND DIARY 

























-0.09	 0.10	 -0.09	 0.93	 -0.33-0.31	
Control	Arm	
(pill	count)	
0.77	 -	 -	 -	 -	
Control	Arm	
(diary)	
1.31	 -	 -	 -	 -	
 
TABLE 5 
A graph of the number of PRN pills taken according to the diary entries plotted 






FIGURE 5: PLOT OF PRN MEDICATION CORRELATION 
	
	
THE AVERAGE SYMPTOMS VERSUS PRN ANTI-EMETIC USE 
ACCORDING TO WHAT PARTICIPANTS RECORDED IN THE DIARIES 
WERE PLOTTED FOR THE INTERVENTION AND CONTROL ARMS. THE 
LINE OF BEST FIT FOR THE INTERVENTION ARM WAS Y= -0.09X + 3.06, 
R² = 0.05 (	
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FIGURE	5 
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FIGURE 7: AVERAGE SYMPTOMS VERSUS PRN ANTI-EMETIC USE 
(CONTROL)  
 
MUSE SCALE  
17 participants completed the study and had MUSE scale results by the end of 
data collection. The MUSE scale results were calculated for each participant at baseline 
then at the end of study using the MUSE scale assessment tool (Cameron et al., 2010). 
The difference between the score for each participant was subtracted to determine what 





























An independent t-test was performed on the difference of the MUSE Scores from 
baseline to end of study, the t-test was stratified by intervention group. It was assumed 
that the MUSE Scale difference would be significantly different between the two arms 
from baseline to end of study. The t-test results were performed on 10 participants in the 
intervention group and 7 participants in the control group. For the intervention group arm 
the mean of score difference was 0.7, SE= 1.39, SD= 4.40 (Table	6). For the control group 
arm the mean of the score difference was 1.86, SE=1.21, SD= 4.99 (Table	 6). The 
alternative hypothesis Ha: diff>0, where Pr (T>t)= 0.67, t (15)=  -0.46 (Table	 6). All 
confidence intervals cross zero, making the results non-statistically significant.  
TABLE 6: T-TEST OF THE DIFFERENCE IN MUSE SCALE RESULTS 
FROM BASELINE TO END OF STUDY BY INTERVENTION GROUP 
 Number of 
Participants Mean SE SD 95% CI 
Intervention 
Arm 
10 0.7 1.39 4.40 -2.4 – 3.85 
Control Arm 7 1.86 2.28 6.04 -3.73 – 7.44 
Combined 17 1.18 1.21 4.99 -1.39 – 3.74 
Difference  -1.16 2.52 - -6.53 -  4.21 
 
Difference= mean (intervention) – mean (control) 
Degrees of freedom=15 
t=-0.46 
Ha: diff <0, Pr (T<t)=0.33 
Ha: diff=0, Pr (|T|<|t|)=0.65 







  Qualitative information was collected for both participants in the control and 
intervention arm as the poster presented by a co-investigator, KS(Smith, 2012). The 
survey asked about the complexity of the regimen and those in the intervention arm were 
further asked about satisfaction questions regarding the pictorial medication calendar 
tool.  The RCT survey did not ask care providers such as nurses or physicians on the 
perceived efficacy of the pictorial calendar tool as this data was collected previously.   
COMPLEXITY OF TREATMENT REGIMEN 
17 participants had final results available for the MUSE scale, with 10 
participants, 58%, in the intervention arm and 7 participants, 41%, in the control arm. Of 
the 17 participants for which results were available for the MUSE scale, 8 participants in 
the intervention group and 3 participants in the control group completely disagreed that 
the medication regimen was complicated, 1 participant in the intervention group and 2 in 
the control group moderately disagreed, none of the participants neither agreed nor 
disagreed, 1 moderately agreed and 2 moderately agreed and no participants completely 









The remainder of the satisfaction survey questions that were answered on a Likert 
scale (Figure	 9) were only targeted towards the intervention arm participants to assess 
their satisfaction with the pictorial calendar.  
I USE THE STUDY CALENDAR TO HELP ME KEEP TRACK OF MY 
MEDICATION (S) 
 
 Of the intervention arm participants who answered the question “I use the study 
calendar to help keep track of my medication(s), none of the participants completely or 
moderately disagreed, 1 neither agreed nor disagreed, 3 moderately agreed and 5 





































THE LAYOUT AND PICTURES OF THE CALENDAR MAKE IT EASY TO 
UNDERSTAND 
 Of the intervention arm participants who provided a response regarding the 
question “the layout and pictures of the calendar make it easy to understand”, 1 
completely disagreed with it’s ease of understanding, none moderately disagreed or 
neither agreed nor disagreed, 3 moderately agreed and 5 completely agreed (Figure	9). 
WHAT MEDICATION (S) YOU NEED TO TAKE 
 Of the intervention arm participants who provided a response to the question “did 
the calendar help you with what medication(s) you need to take”, 1 participant indicated 
completely disagree, none moderately disagreed, 3 neither agreed nor disagreed, 1 
moderately agreed and 5 completely agreed (Figure	9). 
WHEN YOU NEED TO TAKE YOUR MEDICATION (S) 
 Of the intervention arm participants who answered the question “did the 
medication calendar help you decide when you need to take your medication(s)”, none 
completely disagreed or moderately disagreed, 1 neither agreed nor disagreed, 3 
moderately agreed and 5 completely agreed (Figure	9). 
HOW MANY TIMES YOU NEED TO TAKE YOUR MEDICATION (S) 
 Of the intervention arm participants who answered the question “did the 
medication calendar help you with how many times you needed to take your 
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medication(s)”, none answered completely disagree or moderately disagree, 2 neither 
agreed nor disagreed, 2 moderately agreed and 6 completely agreed (Figure	9). 


























































The initial study population involved adjuvant and neo-adjuvant breast cancer 
patients as well as adjuvant colon cancer patients. Due to the large proportion of breast 
cancer patients being female, the majority of the initial participant pool consisted of 
female patients, therefore that may be why of the 17 participants enrolled, 11 were 
female. Adherence as previously discussed may be affected by gender, whereby two 
studies have found that adherence tended to be better in males than females. Therefore, if 
a disparity in gender consists after full data collection, gender must be analyzed as 
confounder.  
After the first 3 months of conducting the study, a request was sent to the Boards 
of Ethics at Waterloo and Western Universities to request expansion of the study to all 
adjuvant and neo-adjuvant solid organ, or non-hematologic malignancies to improve 
enrollment. The final proportions of male to female demographics may therefore change 
as the study proceeds.  
 The average age in both populations was relatively similar whereby the average 
was 57 and 63 years of age in the intervention and control group, respectively. Therefore, 
age as a confounding factor in adherence is not as likely in this population, however an 
analysis of age as confounder was not performed due to the small sample population. A 
multivariate analysis will be considered at final data analysis, if required.  
It must be noted that most adherence studies in the literature that utilize pictorial 
based regimens or visual aids tended to target populations of lower literacy, however, our 
study population tended to have higher literacy with all participants at least attaining a 
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high school education. The statistics in the literature regarding the use of visual aids to 
improve adherence may therefore not be entirely applicable secondary to the difference in 
education level at baseline.  
 The difference in the number of medications taken outside of their oncology 
regimen on a daily basis may affect adherence. Participants in the intervention arm took 
approximately 20% less medications than those in the control arm. Pill burden has been 
previously associated with reduced adherence (Morrow et al., 1988), therefore that may 
need to be taken into consideration during final data analysis as a confounding variable if 
this trend persists.  
 The number of times that participants took medications that are not related to their 
oncologic regimen per day was very similar between the two groups, which reduces pill 
burden and number of times that a participant must remember to take medications per 
day. Therefore, adherence between the two groups would not have been affected by a 
confounding variable of number of times that medications were taken per day.  
Two measures of adherence were utilized in the study including a pill count 
performed by pharmacy staff members that looked at the difference of pills given at 
baseline to pills remaining in vials after each cycle and also a subjective diary in which 
participants were to record the number of anti-emetics taken.  
The calculation of self-reported adherence that was planned on being used was 
not utilized due to the low numbers of enrolled participants that completed the pill count. 
Therefore, this percentage of adherence will be revisited once the full study is complete 
and 174 participants have been enrolled.  
	 51	
A correlation analysis was performed to determine the relationship between 
scheduled pills taken as per the pill count performed by pharmacy staff and that, which 
was reported by the patient as per the recording in the diary. 11 out of 17 participants 
brought back their diaries, therefore only those participants’ data points could be 
analyzed. The p value, was not statistically significant, however there did appear to be a 
trend towards significance, with the p value being slightly above 0.05 and the correlation 
statistic, r being 0.5976. Therefore with a larger sample size, this correlation may present 
differently.  
Another correlation test was also to determine if there was a relationship between 
scheduled pills dispensed to the number of pills taken as per pill count and as per the 
diary. Since participants are intended to take all their scheduled anti-emetics, the 
expected correlation would be 1.  The correlation between scheduled pills dispensed and 
scheduled pills taken, as per pill count was statistically significant with p<0.01 and the 
correlation statistic was 0.9613. This means that there is a strong relationship, which is 
almost 1 to 1 between the number pills taken and the number prescribed pills according to 
pill counts.  
The correlation between scheduled pills dispensed and scheduled pills taken as 
per the diary was also statistically significant at p<0.05, and correlation coefficient was 
0.7060. Therefore, it appears that the overall study population took scheduled anti-
emetics as prescribed. At this point there is a trend towards a moderate relationship 
between the number of taken medications according to pharmacy pill count and recording 
of similar information into the diary logs. 
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One outcome that appeared to be different between both arms was the compliance 
with pill counts. Participants in the control arm were less complaint with pill counts than 
those in the intervention arm. 4 of the 7 participants in the intervention arm that were 
dispensed scheduled medications did not return the medications for a pill count, in 
contrast 2 of the 10 participants in the intervention arm did not return scheduled 
antiemetic medications for a pill count.  
The lack of compliance with pill count could indicate that compliance was poorer 
for the participants in the control arm in general outside of study environment. At this 
point this difference may just be chance as it is not statistically interpreted and is simply 
an observation of the data.  
A spearman’s correlation analysis was performed to determine if there was a 
relationship between the total number of PRN antiemetic pills dispensed and the average 
symptoms of nausea and vomiting that participants experienced.  
Of the 17 participants who completed the study, 7 did not return a diary and 
therefore average symptom score of nausea and vomiting could not be calculated. 
Therefore, according to STATA, 9 study participants could be analyzed. The correlation 
between PRN pills taken as per pill count and the symptoms recorded in the diary were 
not statistically significant, however the p value was close to 0.05 and the correlation 
coefficient, r=0.6471, in comparison the p value was much greater than 0.05 and 
correlation coefficient, r=0.2785 between the pills taken as per the diary and the average 
symptom score. This can be interpreted to mean that the there is a moderate positive 
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relationship between the number of pills taken according to pharmacy count and the 
severity of symptoms. 
Therefore, it appears that at this point in time that there is a stronger correlation 
between pill counts performed by pharmacy staff and the participant’s recorded 
symptoms than there are with the diary, however, due to the low number of diaries 
returned, a larger sample size will be required to determine if the diary is a poor tool for 
assessing concordance.  
A regression analysis was also performed to determine if symptoms of nausea and 
vomiting could predict anti-emetic medication use. There did appear to be a statistically 
significant correlation between the PRN medication use in the intervention arm, as 
reported by pill count, and symptoms of nausea and vomiting, however this prediction 
could not be made for the pill count reported as per the diary. It would seem, according to 
the regression trend and the pill count that as the severity of symptoms increased, the 
number of pills taken according to pill count also increased. According to the preliminary 
regression analysis, symptoms account for approximately 71% of the variation in number 
of medications taken according to pill count.  
Due to the low number of participants in the control arm, a regression analysis 
was not possible. A part of the reason why this may be the case is that many participants 
actually forgot to bring in their PRN anti-emetic vials and generally only brought in the 
scheduled anti-emetic empty vials. In order to determine if the calendar affects the 
participant’s ability to use their PRN anti-emetics as prescribed in accordance with their 
symptoms, further data collection will be required.  
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According to the MUSE Scale author, only fully completed scales are analyzable 
and a score cannot be attained if the participant has elected not to answer a question 
(Cameron et al., 2010).  
For the 17 participants who completed the MUSE scale both at baseline and at 
end of study, a independent sample t-test was performed on the difference of the MUSE 
Scores from baseline to end of study.  The mean MUSE Scale score difference of 
observation in the intervention arm was 0.7 and for the control arm the mean MUSE 
Scale score difference was 1.86. Neither arms appeared to have a significant difference in 
results from baseline to end of study, p=0.6735.  
The MUSE scale results between the intervention and control arm did not appear 
to be significantly different. Therefore, at this point it cannot be assumed that medication 
use and self-efficacy, according to the MUSE scale evaluation, is improved with the use 
of the calendar. With an increase in sample size, it will become clearer whether there is a 
difference in participant confidence and comfort with medication use and whether this 
medication use behaviour changes more or less from baseline to end of study. 
It was anticipated that participants in the intervention arm would have less of a 
change in score from baseline to end of study due to the increased comfort with their 
medication regimen when given the calendar.  
A confounder to this outcome may be that participants were at times randomized, 
consented and completed the MUSE scale before being counseled in pharmacy, therefore 
that would affect how comfortable participants felt at that point.  
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  Subjective information from the participant point of view was collected regarding 
how complex each individual felt regarding their treatment regimen. This question was 
asked to both study arm participants. Participants in the control arm found the treatment 
regimen less complicated overall. The pictorial medication calendar tool may have played 
a factor in this response as those in the intervention arm would have not only been given 
routine care, but also would have received further information from the pictorial 
medication calendar.  
 Participants in the intervention arm were then asked a series of questions 
regarding the pictorial medication calendar. 9 participants in the intervention arm 
answered the survey questions. For the question, which asks whether the participant uses 
the study calendar to help them keep track of medications, the responses were mainly 
positive whereby 89% of participants either moderately or completely agreed that the tool 
helped them keep track of their medications.  
 When asked about whether the layout made the regimen easy to understand, 89% 
either moderately agreed or completely agreed and 1 completely disagreed. Therefore, the 
majority of participants felt that the layout was appropriate for ease of understanding of 
medications to be taken for nausea and vomiting in the setting of their oncologic regimen.  
 When asked about what whether the calendar helps participants know what 
medications to take 67% of participants moderately or completely agreed and the 
remainder of the participants, 23%, felt impartial to the tool’s use for this purpose.  
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 Lastly, when asked regarding whether the tool helped participants know when to 
take their anti-emetic medications, 98% of the participants either moderately or 
completely agreed that the tool was useful.  
Therefore, it appeared that the calendar was a useful tool, subjectively to 
participants involved in the study for ease of medication use. Furthermore, it also appears 
that participants who received the diary felt that their regimen was less complex.  
A planned interim analysis of the data is discussed herein for the purpose of a 
Masters Thesis. The full study is intended to have a sample size of approximately 174 
participants. Data herein may not be statistically significant and may change overtime as 
the sample size increases. An increase normalization of distribution and increased 
analyzable data is expected upon study completion. The authors are aware that statistical 
significance or lack thereof at this point is difficult to prove, but the data provides a 
preliminary analysis.  
The MUSE scale was utilized to determine if comfort with medications improved 
or changed between the two intervention arms from baseline to the end of the second 
cycle of chemotherapy. During the study, some participants were consented to the study 
before being counseled by a pharmacist and others were first counseled on anti-emetics 
given prior to chemotherapy, such as aprepitant and granisetron, the consented to the 
study. This may affect baseline MUSE results since patients may either feel more 
overwhelmed with information or feel more prepared for their chemotherapy when given 
further instructions. This confounder was difficult to control for as CRU staff may be able 
to speak with eligible candidates before entering the chemotherapy suite, such as at a 
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clinic visit or when the participant is at the centre to begin treatment, such as the first day 
of their first cycle.  
 Another important limitation to the willingness to participate in the study is a 
participant being counseled before or after consenting. At times it appears that when 
patients come to the pharmacy, they have been given a large amount of information and 
already want to return home. Therefore, the timing of interaction with the possible 
candidate may have affected willingness to participate in the study.  
On multiple occasions, study participants have indicated to investigators that the 
medication diary utilized to determine adherence was a helpful tool in ensuring that the 
patient remembered to take their medications. Although this is a positive outcome with 
potential for further investigation, it was to act as a control between both the intervention 
and control arm, therefore the involvement of this tool as a factor that affects adherence 
was not accounted for when the study was created. Therefore, the use of the diary as an 
adherence tool may have acted as a confounder in improving adherence in both arms, 
which should become equal in both groups secondary to randomization.  
 Also, although nursing education occurred at baseline, there were multiple 
requests for calendars for participants on the study as the nurses also use the calendar to 
explain the anti-emetic regiment to patients. Therefore, participants on the control arm 
may have inadvertently received a calendar without the knowledge of study personnel. 
Further education occurred of the nursing staff regarding the study process and protocol 
after this issue was brought to the attention of an investigator.  
	 58	
 Participants included information in the diary that was not related to just anti-
emetic medication records and symptoms of nausea and vomiting. Information regarding 
symptoms such as pain, palpitations and constipation were also recorded. Therefore, all 














The use of a picture based medication calendar to improve the outcomes of 
adherence, concordance and self-efficacy, calculated by the MUSE Scale, have yet to be 
determined due to small sample size reported in this interim analysis.  Participants that 
received the calendar appeared to find it useful for medication taking behaviours, with 
approximately 80% of participants either moderately or completely agreed that the diary 
helped them keep track of medications, helped with which medications to take, when to 
take them and how many times per day. We would recommend continued use of the 
calendar as an adjunct tool to routine care due to increased positive feedback regarding 
the tool and its layout; however, in order to validate the primary outcome of efficacy, a 







APPLICATIONS IN PRACTICE  
 
 Before determining if this tool is valid and should be applicable to all 
chemotherapeutic regimens at the LRCP as a standard of care, determining whether 
primary outcome of improved adherence is statistically significant would need to occur. 
Therefore, approximately 140 participants still need to be enrolled to determine whether 
there is quantitative significance to the tool.  
 Furthermore, participant satisfaction with the tool must be taken into 
consideration as a strong variable in use of this tool as part of the standard of care. If the 
tool does not affect adherence as a primary outcome, but participants feel that it affects 
their medication use behaviour in a positive manner, then quality of life measure for 
anxiety due to complexity of medication regimen would need to be assessed to determine 
if this is a significant aid.  
 The continued use of this tool in the meantime as an adjunct is appropriate as the 
tool has shown subjectively, from the participant point of view, that it is useful and 











A scoping review of the literature since the Katz Review published in 2006 (Katz 
MG, 2006) will be performed with the primary objective of determining if there is 
existing literature on the use of visual aids for improvement of medication taking 
behaviours to better guide structuring of visual aids to improve medication adherence. 
The scoping review will be done by two independent reviewers of the following 
databases:  PUBMED, EMBASE and Cochrane. All the selected articles will have 
references reviewed for further applicable studies.  
The scoping review will allow for further information to be gathered on literature 
available on adherence with a larger focus on qualitative literature, if applicable.  
NURSING AND PHARMACIST WORKLOAD 
 Due to the complexity and breadth of the project, data regarding pharmacist and 
nursing workload could not be gathered. Therefore, this data will be assessed separately 
from the Master’s Thesis. Workload will be measured by comparing the number of 
nursing callbacks and pharmacist time spent at the patient counselling and education 
session. 
Workload data will be analyzed using a scatterplot and a line of best fit, if applicable, 
for number of minutes spent counselling participants or contacting participants for any 
reason related to medication use. For example, the adherence rate can be plotted against 
	 62	
the amount of time a pharmacist spends to see if a relationship exists.  Similar analysis 
will be performed with the number of callbacks and patient adherence. 
PARTICIPANT INVOLVEMENT 
Participant involvement in improvement of the tool before dissemination to other 
disease sites and possibly centres would be required to ensure that patient input, which is 
highly valuable in development of adherence tools is sought. Focus groups would be 
required to ensure that patient advocates are able to provide feedback on the tool after its 
use. Also, anonymous questionnaires would be another useful tool to allow for 
participants to give feedback on the tool without creating bias.   
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LETTER OF COPYRIGHT PERMISSIONS 
 
An email from the MUSE Scale tool author, Dr. Kenzie Cameron, was received on 
Wednesday July 10th 2015, which allowed us, the co-investigators, to utilize it for the 
purpose of the Calendar Study project.  
The Open Access Journal, in which the tool was validated, did not return our email 
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12-March-2017, Version 5 
Date: ______________ 
Dear Study Participant: 
I would like to thank you for your participation in the study “A Picture is Worth a Thousand 
Words”.  You were invited to participate in this research study about the use of a calendar 
designed to help patients take their medications.  
 
The data collected for this study will help us to understand how a picture-based medication 
calendar helps patients take their medications. This study included adult patients receiving 
treatment for solid organ cancers.  This calendar may be used for patients with other medical 
conditions in the future.  
Please remember that every effort will be made to make sure that any personal data we collected 
about you is protected.  Once all of the data are collected and reviewed, we plan to share this 
information with other healthcare workers through seminars, conferences, presentations, and 
journal articles.   
If you are interested in receiving information about the results of this study, please provide your 
email address to [Hidden].  When the study is completed [Hidden] will send you a summary of 
the results.  If you have any questions about the study at any time, you can contact [Hidden] by 
email or telephone.  
As with all [Hidden] projects involving human participants, this project received ethics approval 
through [Hidden] Research Ethics Committees.   



















Mira Maximos,  
Student Researcher 
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A Picture is Worth a 
Thousand Words:
Researchers: Mira Maximos, Kelly Smith, Karin Hahn, Venita Harris, Feng Chang, Michael 




A Randomized Controlled Trial to Assess Medication Taking Behaviours
Inclusion Criteria Exclusion Criteria
☐ Adult patient (18 years of age or older) at LRCP 
☐ Receiving chemotherapy treatment for non-metastatic: 
     a. Neoadjuvant OR 
     b. Adjuvant solid organ cancer 
☐ Able to give consent independently 
☐ Be on at least one scheduled medication for                 
management of nausea and vomiting
☐ Did not attain minimum of grade 8 education 
☐ Non-English speaking 
☐ Unable to repeat instructions to research personnel 
☐ Difficulty swallowing 
☐ Planning to receive multiple cycles of chemotherapy at 
     alternate sites other than LRCP
☐ Significant visual impairment 
A randomized, open label study to assess medication-taking behaviours. The study will be 
conducted at the London Health Sciences Centre, London Regional Cancer Program, and it is 




































































































Adapted from Case Report Forms (Visit Checklist Version 1.0) on the National Center for Complementary and 
Integrative Health Website.  
 
Version 2 October 2015 
 
Study Completion 
“A Picture is Worth a Thousand Words: 
A Randomized Controlled Trial to Assess the Influence of a Pictorial Medication 




            /              /                        . 
 d  d m  m     y y y y  
1. Date of final study visit:             /              /                        . 
 d d m m y y y y 
2. Primary reason for terminating participation in the study: 
 Completed study 
 Participant was determined after enrollment to be ineligible (provide comments): 
  
 Participant withdrew consent 
 In the principal investigator’s opinion, it was not in the participant’s best interest 
to continue (provide comments):   
 Adverse event (If checked, complete the AE form.) 
 Death 
 Lost to follow-up 







Study Personnel Signature:  ____________________ Date:  ___________________ 
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APPENDIX K: UNANTICIPATED PROBLEMS FORM 
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